To evaluate the continued safety and performance of the Reva Fantom Sirolismus-Eluting Bioresorbable Coronary Scaffold in nativ coronary arteries that includes incorporation of a deformable expansion technologgy and an enhanced scaffold material (Tyr...

Klinische Forschung - 06.05.2024 - 30.06.2030

Laufend

Projektleitung: Rigger Johannes
Mitarbeiter/innen: Fink Karin, Schneider Irene

A multicenter, international, randomized, active comparator-controlled, double-blind, doubledummy, parallel-group, 2-arm, Phase 3 study to compare the efficacy and safety of the oral FXIa inhibitor asundexian (BAY 2433334) with apixaban for the preve...

Klinische Forschung - 01.06.2023 - 30.06.2024

Abgeschlossen

Projektleitung: Rickli Hans
Mitarbeiter/innen: Fink Karin, Vetsch Susanne

Multi-center, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of self-administered subcutaneous selatogrel for prevention of all-cause death and treatment of acute myocardial infarction in subjec...

Klinische Forschung - 10.01.2022 - 14.01.2026

Laufend

Projektleitung: Maeder Micha
Mitarbeiter/innen: Vetsch Susanne, Fink Karin

This study is a single armed, prospective, multi-center, observational study Planned: up to 40 study sites in the EU and selected non-EU-countries

Klinische Forschung - 21.10.2021 - 31.12.2026

Laufend

Projektleitung: Rigger Johannes
Mitarbeiter/innen: Vetsch Susanne, Fink Karin

Contemporary findings from the ongoing Swiss-AF cohort study (2’415 patients with atrial fibrillation (AF) enrolled, 1’760 patients with available brain imaging) showed that patients with AF have a high burden of cerebral infarcts and other brain les...

Klinische Forschung - 17.06.2021 - 17.06.2025

Laufend

Projektleitung: Ammann Peter
Mitarbeiter/innen: Fink Karin

Treatment patterns and Outcomes across the disease Continuum in patients with CAD and/or PAD The study aims to collect real-world data on treatment patterns and decision points for treatment in patients with coronary artery disease (CAD) or sym...

Klinische Forschung - 14.07.2020 - 14.04.2023

Abgeschlossen

Projektleitung: Rickli Hans
Mitarbeiter/innen: Fink Karin

Post-market registry to evaluate the safety and efficacy of the Supraflex Cruz™ sirolimus-eluting coronary stent system in the treatment of all-comer patients with coronary artery disease

Klinische Forschung - 13.07.2020 - 31.12.2022

Abgeschlossen

Projektleitung: Weilenmann Daniel
Mitarbeiter/innen: Schneider Irene, Fink Karin

Health consequences of the Burden of atrial fibrillation The added information of measuring AF burden and measuring cardiac dimensions and function in an AF patient population where brain MRIs are available, could provide further evidence toward...

Klinische Forschung - 06.04.2020 - 06.04.2024

Abgeschlossen

Projektleitung: Ammann Peter
Mitarbeiter/innen: Altmann David, Fink Karin

Multicenter, randomized, active comparator-controlled, double-blind, double-dummy, parallel group, dose-finding Phase 2 study to compare the safety of the oral FXIa inhibitor BAY 2433334 to apixaban in patients with atrial fibrillation Primary Safet...

Klinische Forschung - 21.01.2020 - 07.12.2021

Abgeschlossen

Projektleitung: Rickli Hans
Mitarbeiter/innen: Fink Karin, Vetsch Susanne

The study aims to collect real-world data on treatment patterns and decision points for treatment in patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) treated with rivaroxaban 2.5 mg[BID] for the prevention of...

Klinische Forschung - 19.11.2019 - 21.12.2021

Abgeschlossen

Projektleitung: Rickli Hans
Mitarbeiter/innen: Fink Karin

Takotsubo Cardiomyopathy, or broken heart syndrome, is a recently described acquired form of cardiomyopathy whose pathophysiology is not well understood and particularly affects postmenopausal women. The exact mechanism is still unclear and large p...

Klinische Forschung - 01.04.2018 - 31.12.2030

Laufend

Projektleitung: Jörg Lucas
Mitarbeiter/innen: Fink Karin, Schneider Irene

Study Hypothesis: In patients with evidence of device-detected sub-clinical atrial fibrillation (SCAF) and additional risk factors for stroke, treatment with apixaban compared with aspirin will reduce the risk of the composite of stroke and systemic...

Klinische Forschung - 01.04.2016 - 01.01.2026

Abgeschlossen

Projektleitung: Ammann Peter
Mitarbeiter/innen: Gemperle Michaela, Brenner Roman, Fink Karin, Vetsch Susanne

To increase our knowledge on structural brain damage and its changes over time in patients with AF 2. To gain additional insights on the incidence and underlying mechanisms of cognitive decline in patients with AF 3. To improve long term risk pre...

Klinische Forschung - 12.06.2014 - 01.01.2032

Laufend

Projektleitung: Ammann Peter
Mitarbeiter/innen: Altmann David, Gemperle Michaela, Kopp Sebastian, Fink Karin, Brenner Roman, Vetsch Susanne

Vorhofflimmern ist die häufigste Herzrhythmusstörung in der Bevölkerung. Die genaue Entstehung und vor allem das Fortschreiten dieser Erkrankung sind jedoch trotz vieler Jahre intensiver Forschung nur unvollständig geklärt. Der Funktionszustand des H...

Klinische Forschung - 01.06.2010 - 01.01.2032

Laufend

Projektleitung: Ammann Peter
Mitarbeiter/innen: Gemperle Michaela, Schneider Irene, Fink Karin

The AMIS Plus national registry collects and analyzes data on patients with acute coronary syndrome (acute myocardial infarction, unstable angina and minimal necrosis) in Switzerland in the pre-admission, hospital and follow-up phases. Emphasis is pl...

Klinische Forschung - 01.01.1997 - 31.12.2030

Laufend

Projektleitung: Rickli Hans
Mitarbeiter/innen: Schneider Irene, Fink Karin